RSV is a leading cause of respiratory tract disease in infants and the elderly. RSV has
limited therapeutic interventions and no FDA-approved vaccine. Gaps in our understanding …

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the
circulation; however, it is currently unknown whether it elicits effective immune responses in …

The acute effects of various respiratory viral infections have been well studied, with
extensive characterization of the clinical presentation as well as viral pathogenesis and host …

Respiratory mucosal immunity induced by vaccination is vital for protection from coronavirus
infection in animal models. In humans, the capacity of peripheral vaccination to generate …

Respiratory tract resident memory T cells (TRM), typically generated by local vaccination or
infection, can accelerate control of pulmonary infections that evade neutralizing antibody. It …

Rapid reaction to microbes invading mucosal tissues is key to protect the host against
disease. Respiratory tissue‐resident memory T (TRM) cells provide superior immunity …

Highlights•Tissue-resident memory T (T RM) cell development after respiratory virus
infection.•Lung T RM cell characteristics, regulation, and function.•T RM cells confer optimal …

Current influenza vaccine strategies have yet to overcome significant obstacles, including
rapid antigenic drift of seasonal influenza viruses, in generating efficacious long-term …

Respiratory mucosal immunity induced by vaccination is vital for protection from coronavirus
infection in animal models. In humans, SARS-CoV-2 immunity has been studied extensively …

The influenza virus poses a global health burden. Currently, an annual vaccine is used to
reduce influenza virus-associated morbidity and mortality. Most influenza vaccines have …